Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $309.7 million.

  • UNITED THERAPEUTICS's Other Operating Expenses rose 21.42% to $100.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $356.9 million, marking a year-over-year increase of 17.09%. This contributed to the annual value of $309.7 million for FY2024, which is 20.27% up from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Other Operating Expenses of $309.7 million as of FY2024, which was up 20.27% from $257.5 million recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's Other Operating Expenses ranged from a high of $532.0 million in FY2020 and a low of $122.5 million during FY2021.
  • Over the past 3 years, UNITED THERAPEUTICS's median Other Operating Expenses value was $257.5 million (recorded in 2023), while the average stood at $239.6 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first tumbled by 76.97% in 2021, then skyrocketed by 69.85% in 2023.
  • Yearly analysis of 5 years shows UNITED THERAPEUTICS's Other Operating Expenses stood at $532.0 million in 2020, then plummeted by 76.97% to $122.5 million in 2021, then climbed by 23.76% to $151.6 million in 2022, then surged by 69.85% to $257.5 million in 2023, then rose by 20.27% to $309.7 million in 2024.